PLIANT THERAPEUTICS, INC. Restructuring Charges
PLIANT THERAPEUTICS, INC. (PLRX) reported Restructuring Charges of $3.80 million for the 5-month period ending 2025-09-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-11
- 2025-09-30: Restructuring Charges 5 month $3.80M.
| Period end | Restructuring Charges 5 month |
|---|---|
| 2025-09-30 | $3.80M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |